Horizon Therapeutics
1 Horizon Way
Deerfield
IL
60015
United States
650 articles about Horizon Therapeutics
-
Horizon Pharma plc to Participate in Upcoming Conferences
11/16/2018
Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conferences
-
Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance
11/7/2018
Quarterly Net Sales Increased 20 Percent to $325.3 Million, a Record for the Company; Third-Quarter 2018 GAAP Net Income of $26.0 Million; Adjusted EBITDA of $149.9 Million
-
The Chicago Tribune Names Horizon Pharma plc a 2018 Top Workplace
11/2/2018
Horizon Pharma plc (Nasdaq: HZNP) has been awarded a 2018 Top Workplaces honor by the Chicago Tribune.
-
Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting
10/29/2018
Horizon Pharma plc announced that more detailed results from the 48 week off-therapy follow-up to the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the American Academy of Ophthalmology (AAO) Annual Meeting, Oct. 27 – 30, 2018, in Chicago, Ill.
-
Horizon Pharma plc to Participate in Investor Conferences in November
10/25/2018
A replay of the webcast will be available for each event.
-
Horizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity
10/25/2018
Horizon Pharma plc (Nasdaq: HZNP) today announced multiple presentations showing that people who have undergone a kidney transplant experience higher rates of uncontrolled gout compared to other renal disease patients, and mortality rates were higher in kidney transplant recipients diagnosed with gout.
-
Horizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting
10/22/2018
Horizon to also host onsite discussion with prominent researchers on pathophysiology of gout
-
FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year
10/18/2018
The Best Small & Medium Workplaces list is one of a series of rankings by Great Place to Work and FORTUNE based on employee feedback from Great Place to Work-Certified™ organizations.
-
Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018
10/10/2018
Horizon Pharma (Nasdaq: HZNP) announced today that its third-quarter financial results will be released on Wednesday, Nov. 7, 2018.
-
Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab
10/4/2018
Horizon Pharma plc (NASDAQ:HZNP) announced new data from the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) showing a majority of patients that had reductions in proptosis at week 24 maintained these reductions 48 weeks following the study completion, or nearly a year off therapy.
-
Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
9/4/2018
Topline results expected in second quarter of 2019
-
Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focus on Rare Diseases
8/8/2018
-- Record Quarterly Orphan and Rheumatology Segment Net Sales of $201.7 Million Increased 17 Percent; Represented 67 Percent of Total Company Net Sales --
-
Catalyst Pharmaceuticals Expands Commercial Leadership Team
8/6/2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
-
Genentech and Horizon Pharma were the only two biopharma companies that made People’s 2018 list of “50 Companies That Care,” a list that highlights how a company makes a difference in the lives of its employees, as well as the communities those companies call home.
-
PEOPLE and Great Place to Work® Name Horizon Pharma plc to 2018 “50 Companies That Care” List
7/25/2018
Horizon Pharma also formally commits to become a Pledge 1% company
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
7/16/2018
Will Represent the Tenth and Eleventh U.S. Patents to be Listed in the Orange Book for RAVICTI
-
Horizon Pharma plc to Release Second-Quarter 2018 Financial Results and Host Webcast on August 8, 2018
7/9/2018
Horizon Pharma plc announced today that its second-quarter financial results will be released on Wednesday, August 8, 2018.
-
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
-
Miracles, it seems, have a high price tag. At least, if those miracles are miracle drugs. There’s no doubt that trends in gene therapy and immuno-oncology are producing drugs that are as close to miraculous as we’re likely to get, doing a great job, generally, in beating back diseases that to thi...
-
Horizon Pharma and the National Organization for Rare Disorders (NORD) launched a new campaign today that recognizes innovation in rare disease therapeutics since the passing of the Orphan Drug Act in 1983.